HopeStage
Back to all studies
CompletedNCT04754750

Monthly and three-month paliperidone treatment and cognition in schizophrenia

About this titleRead the official source — NCT04754750
Medication studyAges 30–69
The study in practice

Understand this study

Who was this study for?

Listed age limits: 30 years to 69 years.

Study phase
Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: January 2015
Recruitment status
Completed
Enrollment listed in the registry
72
Sponsor
Calo Psychiatric Center
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
Not clearly listed
Age range
From 30 Years to 69 Years
Official registry ID
NCT04754750
Official title
Show the full official title

Differences in Lipid and Cognitive Change Between One-month and 3-month Paliperidone Palmitate Treatment in Stable Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Locations not listed

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Calo Psychiatric Center.

Did this study involve medication?

Yes. The study involved medication, including Paliperidone Palmitate 156 MG/ML Prefilled Syringe [Invega] and Paliperidone Palmitate 546 MG Intramuscular Suspension, Extended Release [INVEGA TRINZA].

Who was this study for?

Listed age limits: 30 years to 69 years.

Want to explore more studies?

Explore studies